False Lumen Treatment for Prevention of Aortic Growth Using Shape Memory Polymer - First-in-Human Study (FLAGSHIP_FRA)

NCT ID: NCT06740721

Last Updated: 2026-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-10-01

Study Completion Date

2029-01-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the safety and feasibility of investigational product to reduce aortic dissection false lumen perfusion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Dissection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: Intervention

Device: False Lumen Embolization System Device: IMPEDE-FX RapidFill

Group Type EXPERIMENTAL

False Lumen Embolization System, IMPEDE-FX RapidFill

Intervention Type DEVICE

Embolization of the false lumen of an aortic dissection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

False Lumen Embolization System, IMPEDE-FX RapidFill

Embolization of the false lumen of an aortic dissection

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥18 years of age.
* A candidate for false lumen (FL) embolization with a type B dissection, and no prior primary entry tear/TL treatment, OR
* A candidate for FL embolization with a type B or type A dissection, in whom the primary entry tear/TL was treated in a previous procedure, and is now presenting with a FL requiring treatment.

Exclusion Criteria

* An inability to provide informed consent.
* Enrolled in another clinical study other than a registry.
* Hyperacute or acute aortic dissection (\<15 days from symptom onset).
* Untreated or uncovered primary entry/reentry tear proximal to left subclavian artery (before FL treatment with the investigational product).
* Vascular disease, aortic rupture, and/or anatomy and/or dissection membrane condition that precludes the safe access and positioning of an introducer sheath and delivery (and expansion) of the investigational product into the FL.
* Prior treatment of the FL.
* Planned use of investigational devices to treat the primary entry tear and/or TL.
* Absence of/inability to create a reentry tear/fenestration adequately positioned and large enough to allow introducer sheath access into the FL.
* Planned use of FL embolic devices other than the investigational product.
* Prior abdominal aortic aneurysm (AAA) treatment.
* Planned concomitant major surgery (e.g., gastrointestinal surgery).
* Diagnosed or suspected congenital degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos syndrome).
* Coagulopathy or uncontrolled bleeding disorder.
* Serum creatinine level \>2.5 mg/dL (within 90 days prior to the procedure).
* Cerebrovascular accident within 90 days prior to the procedure.
* Myocardial infarction and/or major heart surgery within 90 days prior to the procedure.
* Atrial fibrillation that is not well rate controlled.
* Unable or unwilling to comply with study follow-up requirements.
* Life expectancy of \<2 years postprocedure.
* Known hypersensitivity or contraindication to platinum, iridium, or polyurethane.
* A condition that inhibits radiographic visualization during the study procedure and planned follow-up imaging.
* History of allergy to contrast medium that cannot be managed medically.
* Uncontrolled comorbid medical condition, including mental health issues, that, in the opinion of the investigator, would adversely affect participation in the study.
* Participant is planning to become pregnant or is currently pregnant or lactating. For participants of child-bearing potential, based on a positive pregnancy test within 7 days prior to the procedure or refusal to use a medically accepted method of birth control for the duration of the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shape Memory Medical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CRD1041

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.